Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 4, 2015, Pages 757-762

  Hwang, In Gyu ^a   Jang, Joung Soon ^a   Oh, Sung Yong ^b   Rho, Myung Hwan ^b   Lee, Suee ^b   Park, Young Suk ^c   Park, Joon Oh ^c   Nam, Eun Mi ^d   Lee, Hyo Rak ^e   Jun, Hyun Jung ^f   Chi, Kyong Choun ^a  

^a Chung Ang University College of Medicine   (South Korea)

^b Dong A University College of Medicine   (South Korea)

^c Samsung Medical Center   (South Korea)

^d Ewha Womans University School of Medicine   (South Korea)

^e Korea Cancer Center Hospital   (South Korea)

^f Seoul Medical Center   (South Korea)

Author keywords

Biliary tract cancer; Fluorouracil; Oxaliplatin; Second line

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PLATINUM COMPLEX;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; INFECTION; INOPERABLE CANCER; LEUKOPENIA; MALE; METASTATIC BILIARY CANCER; METASTATIC BILIARY TRACT CANCER; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; UNRESECTABLE BILIARY CANCER; UNRESECTABLE BILIARY TRACT CANCER; VOMITING; ANALOGS AND DERIVATIVES; BILIARY TRACT NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84925501172     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2691-1     Document Type: Article

References (19)

1. Bae J-M, Won Y-J, Jung K-W, J-G P (2002) Annual report of the Korea central cancer registry program 2000: based on registered data from 131 hospitals. Cancer Res Treat 34(2):77-83
2. Anderson CD, Pinson CW, Berlin J, Chari RS (2004) Diagnosis and treatment of cholangiocarcinoma. Oncologist 9(1):43-57
3. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, Investigators ABCT (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273-1281. doi: 10.1056/NEJMoa0908721
4. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE (2000) Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58(5):920-927
5. Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD (1998) Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res Off J Am Assoc Cancer Res 4(4):1021-1029
6. Andre T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W (2008) Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 99(6):862-867. doi: 10.1038/sj.bjc.6604628
7. Jang JS, Lim HY, Hwang IG, Song HS, Yoo N, Yoon S, Kim YH, Park E, Byun JH, Lee MA, Oh SJ, Lee KH, Kim BS, Oh SC, Kim SY, Lee SJ (2010) Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol 65(4):641-647. doi: 10.1007/s00280-009-1069-7
8. Lim JY, Jeung HC, Mun HS, Lee DK, Paik YH, Lee SJ, Yoon DS, Cho JY (2008) Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. Anticancer Drugs 19(6):631-635. doi: 10.1097/CAD.0b013e3283017f94
9. Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M, Porschen R (2002) Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 87(7):702-704. doi: 10.1038/sj.bjc.6600543
10. Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, Valerio MR, Gulotta G, Tomasello G, Gebbia N, Fulfaro F (2006) Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Annals Oncol 17(Suppl 7):vii68-vii72. doi: 10.1093/annonc/mdl955
11. He S, Shen J, Sun X, Liu L, Dong J (2014) A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother 26(4):243-247. doi: 10.1179/1973947813Y.0000000133
12. Lim KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ (2012) Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. Oncology 83(2):57-66. doi: 10.1159/000338795
13. Oh SY, Jeong CY, Hong SC, Kim TH, Ha CY, Kim HJ, Lee GW, Hwang IG, Jang JS, Kwon HC, Kang JH (2011) Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 29(5):1066-1072. doi: 10.1007/s10637-010-9417-3
14. Roth A, Schleyer E, Schoppmeyer K, Kluge R, Wittekind C, Mossner J, Wiedmann M (2011) Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study. Onkologie 34(8-9):469-470. doi: 10.1159/000331065
15. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Ito Y, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K (2012) Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 30(2):708-713. doi: 10.1007/s10637-010-9553-9
16. Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, Park YS, Kang WK, Lim HY (2012) A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer 48(2):196-201. doi: 10.1016/j.ejca.2011.11.017
17. Lamarca A, Hubner RA, David Ryder W, Valle JW (2014) Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 25(12):2328-2338. doi: 10.1093/annonc/mdu162
18. Katayose Y, Ohtsuka H, Kitamura Y, Masuda K, Nakagawa K, Yamamoto K, Yoshida H, Onogawa T, Motoi F, Naitoh T, Rikiyama T, Egawa S, Unno M (2012) An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. Hepatogastroenterology 59(115):691-695. doi: 10.5754/hge11530
19. Shoda J, Ishige K, Sugiyama H, Kawamoto T (2012) Biliary tract carcinoma: clinical perspectives on molecular targeting strategies for therapeutic options. J Hepatobiliary Pancreat Sci 19(4):342-353. doi: 10.1007/s00534-012-0520-z